These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 31272142)

  • 1. 2018 Guidelines for the management of dyslipidemia.
    Rhee EJ; Kim HC; Kim JH; Lee EY; Kim BJ; Kim EM; Song Y; Lim JH; Kim HJ; Choi S; Moon MK; Na JO; Park KY; Oh MS; Han SY; Noh J; Yi KH; Lee SH; Hong SC; Jeong IK
    Korean J Intern Med; 2019 Jul; 34(4):723-771. PubMed ID: 31272142
    [No Abstract]   [Full Text] [Related]  

  • 2. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 3. Controversies in dyslipidaemia management.
    Stock J
    Atherosclerosis; 2012 Apr; 221(2):321-4. PubMed ID: 22305261
    [No Abstract]   [Full Text] [Related]  

  • 4. AHA/ACC/Multisociety Cholesterol Guidelines: highlights.
    Jialal I; Devaraj S
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719881579. PubMed ID: 31590600
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial commentary: The long and winding road to follow dyslipidemia guidelines.
    Bonaventura A
    Trends Cardiovasc Med; 2024 Aug; 34(6):379-380. PubMed ID: 37673292
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 8. Dyslipidemia in the metabolic syndrome in children.
    Gidding SS
    J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 10. It's never too early to beat your low-density lipoprotein cholesterol.
    Bergerot C; Angoulvant D; Lemesle G; Barone-Rochette G; Mewton N; Mach F
    Arch Cardiovasc Dis; 2021 Jan; 114(1):1-3. PubMed ID: 33509745
    [No Abstract]   [Full Text] [Related]  

  • 11. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J
    Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
    [No Abstract]   [Full Text] [Related]  

  • 12. Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).
    Steinhagen-Thiessen E; Bramlage P; Lösch C; Hauner H; Schunkert H; Vogt A; Wasem J; Jöckel KH; Moebus S
    Cardiovasc Diabetol; 2008 Oct; 7():31. PubMed ID: 18922160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid update 2020 - Introduction and foreword.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):373-374. PubMed ID: 31711789
    [No Abstract]   [Full Text] [Related]  

  • 14. Triglycerides: A reappraisal.
    Wiesner P; Watson KE
    Trends Cardiovasc Med; 2017 Aug; 27(6):428-432. PubMed ID: 28438398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
    Poli A; Visioli F
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
    Orringer CE
    Trends Cardiovasc Med; 2020 Apr; 30(3):151-157. PubMed ID: 31101399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 18. How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines.
    Orringer CE
    Methodist Debakey Cardiovasc J; 2019; 15(1):16-22. PubMed ID: 31049145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 20. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
    Fruchart JC; Santos RD; Aguilar-Salinas C; Aikawa M; Al Rasadi K; Amarenco P; Barter PJ; Ceska R; Corsini A; Després JP; Duriez P; Eckel RH; Ezhov MV; Farnier M; Ginsberg HN; Hermans MP; Ishibashi S; Karpe F; Kodama T; Koenig W; Krempf M; Lim S; Lorenzatti AJ; McPherson R; Nuñez-Cortes JM; Nordestgaard BG; Ogawa H; Packard CJ; Plutzky J; Ponte-Negretti CI; Pradhan A; Ray KK; Reiner Ž; Ridker PM; Ruscica M; Sadikot S; Shimano H; Sritara P; Stock JK; Su TC; Susekov AV; Tartar A; Taskinen MR; Tenenbaum A; Tokgözoğlu LS; Tomlinson B; Tybjærg-Hansen A; Valensi P; Vrablík M; Wahli W; Watts GF; Yamashita S; Yokote K; Zambon A; Libby P
    Cardiovasc Diabetol; 2019 Jun; 18(1):71. PubMed ID: 31164165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.